Triple Negative Breast Neoplasms Clinical Trials

14 recruitingLast updated: June 17, 2026

There are 14 actively recruiting triple negative breast neoplasms clinical trials across 42 countries. Studies span Phase 2, Phase 1, Phase 3. Top locations include Madrid, Spain, Houston, Texas, United States, Nashville, Tennessee, United States. Updated daily from ClinicalTrials.gov.


Triple Negative Breast Neoplasms Trials at a Glance

14 actively recruiting trials for triple negative breast neoplasms are listed on ClinicalTrialsFinder across 6 cities in 42 countries. The largest study group is Phase 2 with 8 trials, with the heaviest enrollment activity in Madrid, Houston, and Nashville. Lead sponsors running triple negative breast neoplasms studies include Merck Sharp & Dohme LLC, Seagen, a wholly owned subsidiary of Pfizer, and Cancer Research UK.

Browse triple negative breast neoplasms trials by phase

Treatments under study

About Triple Negative Breast Neoplasms Clinical Trials

Looking for clinical trials for Triple Negative Breast Neoplasms? There are currently 14 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Triple Negative Breast Neoplasms trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Triple Negative Breast Neoplasms clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 114 of 14 trials

Recruiting
Phase 3

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

Triple Negative Breast Neoplasms
Merck Sharp & Dohme LLC1,000 enrolled261 locationsNCT06841354
Recruiting
Phase 3

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Breast NeoplasmsTriple Negative Breast NeoplasmsHR Low-Positive/HER2-Negative Breast Neoplasms
Merck Sharp & Dohme LLC2,400 enrolled296 locationsNCT06966700
Recruiting
Phase 1Phase 2

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

Cervical CancerUrothelial CarcinomaMelanoma+8 more
Bristol-Myers Squibb1,109 enrolled47 locationsNCT04895709
Recruiting
Phase 1

A Study of Pembrolizumab and Cryoablation in People With Breast Cancer

Breast CancerTriple-Negative Breast CancerMetastatic Breast Cancer+5 more
Memorial Sloan Kettering Cancer Center30 enrolled7 locationsNCT06246968
Recruiting
Phase 1Phase 2

A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer

Carcinoma, Non-Small Cell LungSquamous Cell Carcinoma of Head and NeckOvarian Neoplasms+8 more
Cancer Research UK167 enrolled4 locationsNCT06380816
Recruiting
Phase 2

A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

Metastatic Breast CancerBreast NeoplasmsGastroesophageal Junction Adenocarcinoma+7 more
Seagen, a wholly owned subsidiary of Pfizer172 enrolled141 locationsNCT06157892
Recruiting
Phase 1

A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

Gastric CancerEndometrial CancerHepatocellular Carcinoma+5 more
Seagen, a wholly owned subsidiary of Pfizer714 enrolled61 locationsNCT05208762
Recruiting
Phase 1

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

Triple-Negative Breast CancerGastric CancerOvarian Cancer+25 more
NiKang Therapeutics, Inc.150 enrolled19 locationsNCT06586957
Recruiting
Phase 2

Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer

Triple Negative Breast Neoplasms
Universitaire Ziekenhuizen KU Leuven53 enrolled6 locationsNCT06365788
Recruiting
Phase 1

A Study of LY4170156 in Participants With Selected Advanced Solid Tumors

Carcinoma, Non-Small Cell LungOvarian NeoplasmsUterine Cervical Neoplasms+4 more
Eli Lilly and Company495 enrolled23 locationsNCT06400472
Recruiting
Phase 2

Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery

Triple Negative Breast Neoplasms
UNICANCER220 enrolled20 locationsNCT05973864
Recruiting
Phase 2

Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer

Breast CancerTriple-Negative Breast CancerBreast Neoplasms+5 more
Okayama University23 enrolled3 locationsNCT05485766
Recruiting
Phase 2

Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer

Breast CancerTriple-Negative Breast CancerBreast Cancer Female+8 more
Baylor Breast Care Center185 enrolled2 locationsNCT05020860
Recruiting
Phase 2

Utidelone (UTD1) Plus Capecitabine in Non-pCR TNBC After Neoadjuvant Therapy

Triple Negative Breast Neoplasms
Hunan Cancer Hospital53 enrolled1 locationNCT06385990